DNPH1, which participates in detoxification reactions, particularly against toxic substances like dinitrophenol, has been shown to significantly sensitize BRCA-deficient cancer cells to PARPi and hmdU treatments.[22] Notably, metabolic alterations in breast cancer extend beyond purine metabolism. Here, DNPH1 is linked to breast carcinoma.